Compare TREE & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREE | PRME |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 693.0M | 666.1M |
| IPO Year | N/A | 2022 |
| Metric | TREE | PRME |
|---|---|---|
| Price | $62.65 | $4.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $75.00 | $6.42 |
| AVG Volume (30 Days) | 254.5K | ★ 3.4M |
| Earning Date | 03-02-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $1,059,158,000.00 | $5,977,000.00 |
| Revenue This Year | $22.86 | $111.80 |
| Revenue Next Year | $7.32 | N/A |
| P/E Ratio | $65.15 | ★ N/A |
| Revenue Growth | 37.01 | ★ 647.13 |
| 52 Week Low | $33.50 | $1.11 |
| 52 Week High | $77.35 | $6.94 |
| Indicator | TREE | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 55.49 | 58.57 |
| Support Level | $63.75 | $3.73 |
| Resistance Level | $68.50 | $4.73 |
| Average True Range (ATR) | 3.74 | 0.35 |
| MACD | 0.69 | 0.07 |
| Stochastic Oscillator | 63.49 | 76.54 |
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.